Literature DB >> 1347583

Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning.

M Tenenbein1, S Kowalski, A Sienko, D H Bowden, I Y Adamson.   

Abstract

The drug of choice for the treatment of iron poisoning is desferrioxamine, though the best route of administration, dose, and duration of treatment are unclear. We report fatal lung injury in four patients who were treated with continuous intravenous infusions. The patients, aged 19-26 years, had received desferrioxamine infusions of 15 mg/kg per h for 65-92 h. Respiratory distress developed after 32-72 h. The patients met clinical, physiological, and necropsy criteria for the diagnosis of adult respiratory distress syndrome (ARDS); none had any of the known risk factors for the development of this disorder. We reviewed the records of forty-three iron-poisoned patients treated with desferrioxamine infusions. No patient treated for less than 24 h had pulmonary complications; however, of the fourteen treated for longer than 24 h, four were the patients with ARDS and four others had pulmonary oedema of other causes. We suggest that the pulmonary complications are caused by continuous infusion of desferrioxamine and that the ARDS in these patient was a consequence of free-radical generation. We recommend that desferrioxamine infusion should not be administered for longer than 24 h.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1347583     DOI: 10.1016/0140-6736(92)90598-w

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  12 in total

1.  Protective effect of vitreous against hemoglobin neurotoxicity.

Authors:  Jing Chen-Roetling; Kathleen A Regan; Raymond F Regan
Journal:  Biochem Biophys Res Commun       Date:  2018-06-06       Impact factor: 3.575

Review 2.  Clinical applications of commonly used contemporary antidotes. A US perspective.

Authors:  C A Bowden; E P Krenzelok
Journal:  Drug Saf       Date:  1997-01       Impact factor: 5.606

3.  Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial.

Authors:  Magdy Selim; Lydia D Foster; Claudia S Moy; Guohua Xi; Michael D Hill; Lewis B Morgenstern; Steven M Greenberg; Michael L James; Vineeta Singh; Wayne M Clark; Casey Norton; Yuko Y Palesch; Sharon D Yeatts
Journal:  Lancet Neurol       Date:  2019-03-18       Impact factor: 44.182

4.  How I treat and manage strokes in sickle cell disease.

Authors:  Adetola A Kassim; Najibah A Galadanci; Sumit Pruthi; Michael R DeBaun
Journal:  Blood       Date:  2015-03-30       Impact factor: 22.113

5.  Intentional iron overdose: an institutional review.

Authors:  S Kroeker; G Y Minuk
Journal:  CMAJ       Date:  1994-01-01       Impact factor: 8.262

Review 6.  Iron homeostasis and toxicity in retinal degeneration.

Authors:  Xining He; Paul Hahn; Jared Iacovelli; Robert Wong; Chih King; Robert Bhisitkul; Mina Massaro-Giordano; Joshua L Dunaief
Journal:  Prog Retin Eye Res       Date:  2007-08-11       Impact factor: 21.198

7.  Assessment of the developmental toxicity of deferoxamine in mice.

Authors:  M A Bosque; J L Domingo; J Corbella
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

8.  Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity.

Authors:  E E Voest; J P Neijt; J E Keunen; A W Dekker; B S van Asbeck; J W Nortier; F E Ros; J J Marx
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 9.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

10.  Retinal iron homeostasis in health and disease.

Authors:  Delu Song; Joshua L Dunaief
Journal:  Front Aging Neurosci       Date:  2013-06-28       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.